Invivoscribe obtained CE-IVDR certification for its IdentiClone Dx IGH assay, a B-cell clonality test detecting immunoglobulin heavy chain (IGH) gene rearrangements in suspected lymphoproliferative disorders. The assay is the first IVDR-certified kit in Europe for clonal immunoglobulin gene rearrangements and is classified as Class C (high risk) under IVDR. The company expects commercial availability in the next month.